Holoxan (ifosfamide) powder for solution for injections 1g. vial №1


Manufacturer: Germany



tumors of the testicles

As part of the combined chemotherapy of patients with advanced stage II-IV tumors according to the TNM (international classification of malignant tumors) classification (seminomas and non-seminomas) that did not respond enough or did not respond at all to primary chemotherapy.

Cervical carcinoma (carcinoma of the cervix)

Palliative combined chemotherapy with cisplatin / ifosfamide (without additional combined drugs) for stage IV cervical carcinoma according to the classification of the International Federation of obstetrics and gynecology (FIGO) (if radical surgical treatment or radiation therapy is not possible), as an alternative to palliative radiation therapy.

Breast cancer

As palliative therapy for common resistant or recurrent breast cancer.

Non-small cell bronchial carcinoma

As a monotherapy or as part of combined chemotherapy for patients with inoperable or metastatic tumors.

Small cell bronchial carcinoma

As part of combined chemotherapy.

Soft tissue sarcoma (including osteosarcoma and rhabdomyosarcoma)

As a monotherapy or as part of combined chemotherapy for rhabdomyosarcoma or osteosarcoma if standard treatment is ineffective. As a monotherapy or as part of combined chemotherapy for other soft tissue sarcomas when surgical and radiation therapy is ineffective.

ewing sarcoma

As part of combined chemotherapy in case of inefficiency of primary cytostatic therapy.

non-Hodgkin’s lymphoma

As part of combined chemotherapy, patients with high-grade non-Hodgkin’s lymphoma did not respond sufficiently or did not respond at all to primary therapy. As part of the combined therapy of patients with recurrent tumors.


For the treatment of patients with Hodgkin’s disease, especially those with a progressive course or at the beginning of a relapse (duration of complete remission is less than one year), after unsuccessful primary chemotherapy or radiochemotherapy under combined chemotherapy regimens, such as the MINE Protocol.